Azenta, Inc. (AZTA)
NASDAQ: AZTA · Real-Time Price · USD
32.05
+1.45 (4.74%)
Oct 15, 2025, 4:00 PM EDT - Market closed
Azenta Revenue
Azenta had revenue of $143.94M in the quarter ending June 30, 2025, a decrease of -0.24%. This brings the company's revenue in the last twelve months to $668.82M, up 12.46% year-over-year. In the fiscal year ending September 30, 2024, Azenta had annual revenue of $656.32M, down -1.32%.
Revenue (ttm)
$668.82M
Revenue Growth
+12.46%
P/S Ratio
2.22
Revenue / Employee
$202,673
Employees
3,300
Market Cap
1.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 656.32M | -8.75M | -1.32% |
| Sep 30, 2023 | 665.07M | 109.57M | 19.73% |
| Sep 30, 2022 | 555.50M | 41.80M | 8.14% |
| Sep 30, 2021 | 513.70M | 125.17M | 32.21% |
| Sep 30, 2020 | 388.54M | 54.36M | 16.27% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AZTA News
- 20 hours ago - Azenta to Host Investor Day at its Biorepository Facility in Indianapolis, Indiana - PRNewsWire
- 2 months ago - Azenta, Inc. (AZTA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance - PRNewsWire
- 2 months ago - Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology - PRNewsWire
- 2 months ago - Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care - PRNewsWire
- 2 months ago - Azenta to Participate in 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference - PRNewsWire
- 3 months ago - Azenta Announces Fiscal 2025 Third Quarter Earnings Conference Call and Webcast - PRNewsWire
- 5 months ago - Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development - PRNewsWire